All Covid-19 vaccines from India being developed for storage at 2-8 deg Celsius: DBT Secy

Logistics at many stages have been worked out keeping this target temperature in mind to meet storage availability.

Press Trust of India January 07, 2021 09:27:52 IST
All Covid-19 vaccines from India being developed for storage at 2-8 deg Celsius: DBT Secy

DBT Secretary Renu Swarup.

All Indian vaccines being developed against the coronavirus can be stored at 2-8 degrees Celsius as the logistics have been worked out considering temperature as a factor, Department of Biotechnology Secretary Renu Swarup said on Tuesday. Swarup said Bharat Biotech's COVID-19 vaccine Covaxin and Oxford-AstraZeneca's Covishield have robustly undergone immunoassay lab tests. (For) all our vaccines, we are looking at right now...(we) are targeting 2-8 degree because our logistics are worked out on that basis, and we are working on that, Swarup said at a press briefing.

The DNA vaccine candidate being developed by Zydus Cadila, and the Biological E's mRNA vaccine work at storage temperatures of 2-8 degrees Celsius, she added.

Unlike the Pfizer and Moderna which requires a minus 70 degree Celsius (cold) chain, this (the Biological E's vaccine candidate) is basically at the 2-8 degree Celsius, Swarup said. The Zydus Cadila candidate has been granted approval to conduct the phase-3 trial while the Biological E candidate is in its phase-1 clinical trial stage.Swarup said Dr Reddy's Laboratories has partnered with Russia's Gamaleya Institute and a vaccine is being developed for India targeting storage at 2-8 degrees Celsius.

They (Dr Reddy's Laboratories) have started phase 2/3 trials in the country. They have completed the first part of the phase 2 trial on 1,000 subjects, and they are now looking at interim data which is to be analysed. They also have large global trials, like the Astrazeneca and that data is also being looked at. What they are targeting is for India to try and see how it could be at 2-8 degrees, Swarup said.

There are 30 vaccine candidates in India at different stages. The country's drugs regulator Sunday granted emergency use approval to Oxford-AstraZeneca's Covishield and also to the indigenously developed Covaxin even though not enough data on the latter's efficacy and safety was available, which has triggered a debate.

Seeking to ally apprehensions on this, Swarup said, These two vaccines which have been spoken about right now, we have had the robust immunoassays which have been studied through within the laboratories.

Referring to the Translational Health Science and Technology Institute (THSTI), Faridabad, an institute under the DBT, Swarup said the lab has sets of immunoassays – which are biochemical tests – that run all these vaccines through them. So anything that comes out of this immunoassay lab gives you the confidence that it has gone through the robust assay system which gives you the immunogenicity and the safety data as we move forward, Swarup said.

Updated Date:

also read

Why approval for Bharat Biotech’s iNCOVACC, world’s first intranasal COVID vaccine, is a big deal
Explainers

Why approval for Bharat Biotech’s iNCOVACC, world’s first intranasal COVID vaccine, is a big deal

Bharat Biotech says iNCOVACC has several advantages including being non-invasive and needle-free. Trained healthcare workers are not required to administer it, and it can eliminate needle-associated risks such as injuries and infections

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval
Health

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval

iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose

Cannot be liable to compensate for deaths due to Covid-19 vaccines: Centre tells SC
India

Cannot be liable to compensate for deaths due to Covid-19 vaccines: Centre tells SC

The affidavit was filed in response to a plea by the parents of two girls who died due to adverse effects following Covid-19 vaccination. It said vaccines made by third parties had undergone regulatory review, and holding the state liable to provide compensation may not be legally sustainable